UY37834A - Tratamiento de mh con compuestos de pirimidinadiona - Google Patents

Tratamiento de mh con compuestos de pirimidinadiona

Info

Publication number
UY37834A
UY37834A UY0001037834A UY37834A UY37834A UY 37834 A UY37834 A UY 37834A UY 0001037834 A UY0001037834 A UY 0001037834A UY 37834 A UY37834 A UY 37834A UY 37834 A UY37834 A UY 37834A
Authority
UY
Uruguay
Prior art keywords
pirimidinadiona
compounds
treatment
methods
hypertrophic cardiomyopathy
Prior art date
Application number
UY0001037834A
Other languages
English (en)
Inventor
J Semigran Marc
H Lee June
Joseph Lambing
Eric Green
Marc Evanchik
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of UY37834A publication Critical patent/UY37834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Se proveen métodos para tratar miocardiopatía hipertrófica y disfunción diastólica.
UY0001037834A 2017-08-04 2018-08-06 Tratamiento de mh con compuestos de pirimidinadiona UY37834A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15

Publications (1)

Publication Number Publication Date
UY37834A true UY37834A (es) 2019-02-28

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037834A UY37834A (es) 2017-08-04 2018-08-06 Tratamiento de mh con compuestos de pirimidinadiona

Country Status (15)

Country Link
US (3) US20200054636A1 (es)
EP (1) EP3661514A1 (es)
JP (2) JP2020529996A (es)
KR (1) KR20200035973A (es)
CN (2) CN111182901A (es)
AU (2) AU2018311974B2 (es)
CA (1) CA3071948A1 (es)
IL (1) IL272300A (es)
MA (1) MA49760A (es)
MX (3) MX2020001406A (es)
RU (1) RU2020109345A (es)
SG (2) SG10202112960QA (es)
TW (1) TW201916882A (es)
UY (1) UY37834A (es)
WO (1) WO2019028360A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
MX2022005465A (es) * 2019-11-10 2022-08-08 Myokardia Inc Metodos de tratamiento con modulador de miosina.
CN115515941A (zh) * 2020-01-28 2022-12-23 梯瓦制药国际有限责任公司 Mavacamten的固态形式及其制备工艺
CN116490185A (zh) * 2020-08-28 2023-07-25 迈奥卡迪亚公司 用肌球蛋白调节剂治疗的方法
AU2021381664A1 (en) 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
MX2023008810A (es) * 2021-02-01 2023-08-04 Dr Reddys Laboratories Ltd Proceso de preparacion de mavacamten y formas en estado solido del mismo.
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
TW202320763A (zh) * 2021-07-16 2023-06-01 美商胞質動力學公司 治療肥厚性心肌病之方法
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117929C2 (uk) * 2013-06-21 2018-10-25 Міокардіа, Інк. Сполуки піримідиндіону, спрямовані проти станів серцево-судинної системи

Also Published As

Publication number Publication date
AU2024203872A1 (en) 2024-06-27
WO2019028360A1 (en) 2019-02-07
EP3661514A1 (en) 2020-06-10
MX2024000348A (es) 2024-01-26
AU2018311974A1 (en) 2020-02-06
JP2020529996A (ja) 2020-10-15
CA3071948A1 (en) 2019-02-07
SG10202112960QA (en) 2021-12-30
MX2020001406A (es) 2020-03-09
US20200054636A1 (en) 2020-02-20
US20220226324A1 (en) 2022-07-21
RU2020109345A (ru) 2021-09-06
AU2018311974B2 (en) 2024-03-07
JP2023065372A (ja) 2023-05-12
MX2024008096A (es) 2024-07-15
IL272300A (en) 2020-03-31
SG11202000549TA (en) 2020-02-27
US20220313695A1 (en) 2022-10-06
MA49760A (fr) 2020-06-10
CN111182901A (zh) 2020-05-19
CN118593507A (zh) 2024-09-06
KR20200035973A (ko) 2020-04-06
TW201916882A (zh) 2019-05-01

Similar Documents

Publication Publication Date Title
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CL2019001554S1 (es) Automóvil.
ECSP17073743A (es) Moduladores de k-ras
EA201691991A1 (ru) Мультиспецифические антитела
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2017002238A1 (es) Método de tratamiento con tradipitant
EA201991818A1 (ru) Лечение рака
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
EA202091881A1 (ru) Соединения для лечения боли
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
UY38352A (es) Inhibidores de integrina alfavbeta6
UY36286A (es) Tratamientos médicos basados en anamorelina
CL2020000973A1 (es) Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.
MX2023008764A (es) Composiciones y metodos para prevenir y tratar afecciones.
CL2019001114S1 (es) Componente de retención.
CL2019001121S1 (es) Cepillo de dientes.
CL2019001123S1 (es) Cepillo de dientes.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110